AGP Picks
View all

Paxman launches neuropathy system to curb chemotherapy nerve damage

Nov. 5, 2026
Paxman launches neuropathy system to curb chemotherapy nerve damage
By AI, Created 07:19 UTC, Nov 05, 2026, AGP -

Paxman has begun commercial rollout of its Paxman Neuropathy System in six European markets after recent regulatory approvals, aiming to reduce chemotherapy-induced peripheral neuropathy, a debilitating side effect that can force treatment changes and hurt quality of life. The launch is backed by new clinical data and comes as the company expands beyond scalp cooling for the first time.

Why it matters: - Chemotherapy-induced peripheral neuropathy, or CIPN, can cause numbness, pain, tingling and loss of sensation in the hands and feet. - CIPN can make walking, writing, dressing and sleeping difficult. - Symptoms can last long after treatment ends. - In severe cases, CIPN can lead to chemotherapy dose reductions, delays or discontinuation. - The condition remains one of oncology’s biggest unmet needs because there is no established standard preventive therapy. - Paxman’s new system targets that gap by trying to reduce the risk and severity of CIPN.

What happened: - Paxman announced the commercial launch of the Paxman Neuropathy System, a cryocompression device designed to help prevent CIPN. - The launch is Paxman’s first major product expansion beyond scalp cooling for chemotherapy-induced hair loss. - The system is launching in the UK, France, Germany, the Netherlands, Spain and Italy after recent regulatory approvals. - Pilot programs are already underway in the UK. - Expansion into additional European centers is expected in the coming months.

The details: - The Paxman Neuropathy System uses cryocompression technology. - Paxman says the technology is intended to help patients remain on prescribed treatment regimens. - The launch coincides with publication of clinical data from a prospective multicentre Phase I/II study in JCO Oncology Advances. - The study evaluated the system in patients receiving taxane-based chemotherapy. - Researchers found the device was safe and well tolerated. - The study also found low rates of CIPN. - Among 146 evaluable patients, no participants developed severe neuropathy. - Patient-reported clinically significant sensory symptoms stayed low throughout follow-up. - A major scientific review in Therapeutic Advances in Medical Oncology also was published alongside the launch. - The review examined the causes, impact and prevention strategies for CIPN. - The review highlighted cryotherapy and cryocompression as promising emerging interventions.

Between the lines: - Paxman is broadening its oncology portfolio beyond a single side-effect category. - The move builds on more than 25 years of experience in scalp cooling and follows the 2025 acquisition of Dignitana. - The timing suggests Paxman is positioning cryocompression as the next phase of its side-effect management business. - The clinical data and review publication give the launch a scientific backdrop that may help support adoption. - Ongoing studies indicate the evidence base is still developing, even as commercialization begins.

What's next: - Further research is continuing in the randomized SWOG S2205 ICE COMPRESS study in the United States. - Another clinical trial is underway at Dana-Farber Cancer Institute evaluating the Paxman Neuropathy System. - Paxman expects broader European expansion beyond the initial launch markets as more centers come online. - The company’s next test will be whether clinical evidence and regulatory momentum translate into routine use in cancer care.

The bottom line: - Paxman is betting that cryocompression can become a practical tool against one of chemotherapy’s most difficult side effects, and the company is moving from evidence to commercial rollout while more data are still being collected.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Madrid Wire

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Madrid Wire

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.